medline.ch Onkologie Urologische Tumoren

	Randomized trial of adjuvant 5-FU-platinum vs paclitaxel-platinum for high-risk penile cancer. J Natl Cancer Inst Noronha V, Menon N, Shah M, Patil V, Dhanawat A, Prakash G, Pal M, Arora A, Misra A, Goud S, More S, Yadav A, Murthy V, Maitre P, Menon S, Popat P, Sable N, Agarwal A, Rangarajan V, Shetake A, Badwe R, Prabhash K. PMID: 42636270 [PubMed - as supplied by publisher]
	A Phase 2 Study of Berzosertib in Combination with Carboplatin compared to Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer. Cancer Res Commun Choudhury AD, Zhong C, Xie W, Kochupurakkal BS, Wu PI, Riaz IB, Liu R, Yang DD, Folefac E, Lee D, Parikh M, Einstein DJ, Kessler ER, Mayer T, McKay RR, Pace A, Mouw KW, Chen L, Adalsteinsson VA, Van Allen EM, Kunos CA, Gore SD, Das B, D'Andrea A, Taplin ME, Shapiro GI. PMID: 42636061 [PubMed - as supplied by publisher]
	A single-center study of prognostic impact and treatment implications of cribriform pattern in prostate cancer. Discov Oncol Handke A, Dellino M, Orf C, Wang N, Darr C, Bach P, Roghmann F, Tully KH. PMID: 42635876 [PubMed]
	Multimodal artificial intelligence in prostate cancer: integrating multiparametric MRI with clinicopathological, molecular, and functional imaging data. Abdom Radiol (NY) Fujiwara M, Yoshida S, Banerjee I, Arita Y, Fujii Y. PMID: 42635792 [PubMed - as supplied by publisher]
	Outcomes of [(177)Lu]Lu-PSMA-617 radioligand therapy with and without concurrent enzalutamide in metastatic castration-resistant prostate cancer: a single-center retrospective study. Eur J Nucl Med Mol Imaging Arslan DF, Civan C, Sanli MO, Has Simsek D, Ekenel M, Basaran M, Erdem S, Ozcan F, Kuyumcu S, Sanli Y. PMID: 42635771 [PubMed - as supplied by publisher]
	Individual and composite socioeconomic inequalities in diagnosis, treatment, and survival of kidney cancer: a population-based analysis of the SEER database. World J Urol Zhang S, Sheng Y, Wang Y, Zhu S, Xiong H. PMID: 42635662 [PubMed - indexed for MEDLINE]
	Patient and primary care clinician perspectives on polygenic risk scores for prostate cancer screening: a national qualitative study. Genet Med Clayman ML, Cheam L, Gillespie C, Antwi AA, Anderson E, Danowski ME, Brunette CA, Song V, Grant CE, Scheuner MT, Wiener RS, Vassy JL. PMID: 42635031 [PubMed - as supplied by publisher]
	DYNAMIC ANDROGEN RESPONSE INDEX AND ITS ASSOCIATION WITH BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY FOLLOWING NEOADJUVANT ANDROGEN DEPRIVATION THERAPY. Exp Oncol Afanasiev Y, Vozianov S, Danylets R, Grygorenko V, Shulyak O, Sosnin M, Kholokharenko I. PMID: 42634840 [PubMed - indexed for MEDLINE]
	The Synergistic Role of Phenolic Compounds in Docetaxel Chemoresistance in Prostate Cancer: A Systematic Review and Meta-Analysis. Curr Pharm Des Tatiparthi R, Aljabali AAA, Mishra Y, Mishra V. PMID: 42634543 [PubMed - as supplied by publisher]
	Editorial Comment on Exploratory Time-Dependent Patterns in Estimated Treatment Effect of Talazoparib Plus Enzalutamide in HRR Non-Deficient or Unknown Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the TALAPRO-2 Trial. Int J Urol Utsumi T. PMID: 42634253 [PubMed - in process]
	Diet and risk of bladder cancer: a systematic review of epidemiological evidence. BJU Int Miyajima K, Miszczyk M, Roessler N, Inoue S, Rajwa P, Matsukawa A, Urabe F, Mori K, Yanagisawa T, Karakiewicz PI, Teoh JY, Briganti A, Yang L, Schernhammer E, Kimura T, Shariat SF. PMID: 42634248 [PubMed - as supplied by publisher]
	Skin Rash Management Based on Early Elevation in the Eosinophil Proportion Within 3â€‰Months of Initiating Apalutamide for Prostate Cancer. Cancer Rep (Hoboken) Koguchi D, Tsumura H, Tabata KI, Satoh T, Tachibana T, Hirano S, Ikeda M, Ishii D, Matsumoto K. PMID: 42634213 [PubMed - indexed for MEDLINE]
	Early patient-reported outcomes and decisional regret after robot-assisted radical prostatectomy: A prospective single-center cohort study. J Robot Surg Roh Y, Shin D, Park YH, Cho HJ, Ha US, Hong SH, Lee JY, Bang S. PMID: 42634057 [PubMed - indexed for MEDLINE]
	Single-port versus multi-port robot-assisted partial nephrectomy for predominantly low-complexity renal tumors: a systematic review and meta-analysis. J Robot Surg Liu W, Su J. PMID: 42634038 [PubMed - indexed for MEDLINE]
	Stereotactic Prostate Cancer Ablative Re-Irradiation: A Systematic Review and Meta-Analysis (SPARE). Prostate Gouveia AG, Tao J, Pond G, Dong K, Ye A, Rosa AA, Palhares DM, Villafuerte CJQ, Anselmo P, Moraes FY, Arcidiacono F, Olson R, Tsakiridis T. PMID: 42633701 [PubMed - as supplied by publisher]
	circ-ITCH suppresses prostate cancer cell proliferation, migration and invasion in-vitro through the miR-106b-5p/SETD2 axis. Pak J Pharm Sci Jiang J, Wei J, Chen F, Li Y, Ba L, Pan B. PMID: 42633546 [PubMed - indexed for MEDLINE]
	Real-World Comparison of Abiraterone Acetate Versus Docetaxel in Combination With Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Cohort Study From Vietnam. Cancer Control Nguyen H, Nguyen H, Nguyen HX, Truong M, Ngo T. PMID: 42633534 [PubMed - indexed for MEDLINE]
	Mitochondrial convergence of ferroptosis and cuproptosis in castration-resistant prostate cancer: From metabolic vulnerabilities to therapeutic targeting. BBA Adv Wang CL, Lv JT, Liu SJ, Zhang YY, Wang SL, Song SQ. PMID: 42633322 [PubMed]
	Prognostic value of CD103+ tumor-infiltrating lymphocytes in bladder cancer: A systematic review and meta-analysis. Urol Oncol Teixeira EG, Torres LAF, Defante MLR, de Azevedo FM, Souza VC. PMID: 42632294 [PubMed - as supplied by publisher]
	A phase-specific benefit-toxicity framework for perioperative trials in muscle-invasive bladder cancer: A focused review andtrial-level mapping analysis. Urol Oncol Shinohara M, Narita T, Hamaya T, Ichiyama T, Fujita N, Okamoto T, Yamamoto H, Ohyama C, Hatakeyama S. PMID: 42632293 [PubMed - as supplied by publisher]

Artikel 1 - 20 / 180923

Seite 1 von 9047

Suchbegriffe

Benutzen Sie englische Suchbegriffe für Ihre Suche in medline.ch.

Übersetzungsproblem?

mehr >>



		Zeitfenster

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Datenschutzerklärung / Privacy Policy \| Werbung